Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers

Modern Pathology

Volumn 16, Issue 5, 2003, Pages 491-504

  Legendre, Hugues ^a   Decaestecker, Christine ^a   Nagy, Nathalie ^b   Hendlisz, Alain ^a   Schüring, Max Peter ^c   Salmon, Isabelle ^b   Gabius, Hans Joachim ^c   Pector, Jean Claude ^a   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Colorectal cancer; Connective tissue; Dukes classification; Epithelium; Galectin 3; MIF; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GALECTIN 3; IMMUNOMODULATING AGENT; IRINOTECAN; LEVAMISOLE; MACROPHAGE MIGRATION INHIBITION FACTOR; OXALIPLATIN; PROTEIN P53; RNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL TUMOR; CONNECTIVE TISSUE; CONTROLLED STUDY; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER METASTASIS; MALE; MICROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

EID: 0038823600     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000068235.45178.C1     Document Type: Article

References (62)

1. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483-93.
2. Maghfoor I. Colorectal cancer. The Lancet 1999;353:391-9.
3. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-2424.
4. Cohen AM. Colorectal cancer: evolving concepts in diagnosis, treatment, and prevention. CA Cancer J Clin 1999;49:199-201.
5. Wils JA. Adjuvant treatment in Dukes' B and C disease. Annu Oncol 2000;11(Suppl):37-43.
6. Lindblom A. Improved tumor staging in colorectal cancer. N Engl J Med 1998;339:264-5.
7. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 1998;41:1033-49.
8. Gennari L, Doci R, Rossetti C. Prognostic factors in colorectal cancer. Hepatogastroenterology 2000;47:310-4.
9. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323-32.
10. Freedman LS, Macaskill P, Smith AN. Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 1984;2:733-6.
11. Newland RC, Dent OF, Lyttle MN, Chapuis PH, Bokey EL. Pathologic determinants of survival associated with lymph node metastases. Cancer 1994;60:2318-24.
12. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988;319:525-32.
13. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-6.
14. Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, Ben-Sasson S, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 2001;98:2640-5.
15. Yogeeswaran G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983;38:289-350.
16. Alhadeff JA. Malignant cell glycoproteins and glycolipids. Crit Rev Oncol Hematol 1989;9:37-107.
17. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
18. Gabius HJ. Concepts of tumor lectinology. Cancer Invest 1997;15:454-64.
19. Brockhausen I, Schutzbach J, Kuhns W. Glycoproteins and their relationship to human disease. Acta Anat 1998;161:36-78.
20. Gabius HJ. Animal lectins. Eur J Biochem 1997;243:543-76.
21. Hirabayashi J (editor). Recent topics on galectins. Trends Glycosci Glycotechnol 1997;9:1-180.
22. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
23. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999; 1473:172-85.
24. Sano H, Liu FT. Galectins: another family of chemoattractants? Mod Asp Immunobiol 2001;2:4-6.
25. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995;55:2191-9.
26. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 2001;127:375-86.
27. Bresalier RS, Byrd JC, Wang L, Raz A. Colon cancer mucin: a new ligand for the β-galactoside-binding protein galectin-3. Cancer Res 1996;56:4354-7.
28. Itzkowitz SH. Galectins. Multipurpose carbohydrate-binding proteins implicated in tumor biology. Gastroenterology 1997;113:2003-5.
29. Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 1993;90:3466-70.
30. Castronovo V, Campo E, Van Der Brule FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 1992; 84:1161-9.
31. Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, Cleary KR, et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991;51:387-93.
32. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995;75:2818-26.
33. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 1999;15:143-8.
34. Choufani G, Ghanooni R, Decaestecker C, Delbrouck K, Simon P, Schuring MP, et al. Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases-3/9, retinoic acid receptor-beta, and anti-apoptotic galectin-3. Laryngoscope 2001;111:1656-62.
35. Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med 1999;190:1367-70.
36. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 2000;10:359-66.
37. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000;20:751-62.
38. Shkolnik T, Livni E, Reshef R, Lachter J, Eidelman S. Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen in colorectal cancer and colonic premalignant lesions. Am J Gastroenterol 1987;82:1275-8.
39. Reshef R, Livni E, Lachter J, Suprun H, Eidelman S, Shkolnik T. Colon cancer bearing rats produce a lymphokine which induces macrophage migration inhibition (MIF) in vitro. Comp Immunol Microbiol Infect Dis 1988;11:61-9.
40. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
41. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001;11:12-26.
42. Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996;2:143-9.
43. Nagy N, Bronckart Y, Camby I, Phillipart P, Lahm H, Kaltner H, et al. Galectin-8 expression decreases in cancer as compared to normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration. Gut 2002;50:392-401.
44. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, De Decker R, et al. Molecular characterization of cell-substratum attachments in human glial tumors relates to prognostic features. Glia 2001;36:375-90.
45. Hyndman D, Cooper A, Pruzinsky S, Coad D, Mitsuhashi M. Software to determine optimal oligonucleotide sequences based on hybridization simulation data. Biotechniques 1996; 20:1090-7.
46. Decaestecker C, van Velthoven R, Petein M, Janssen T, Salmon I, Pasteels JL, et al. The use of the decision tree technique and image cytometry to characterize aggressiveness in World Health Organization (WHO) grade II superficial transitional cell carcinomas of the bladder. J Pathol 1996;178:274-83.
47. Francois C, Decaestecker C, Petein M, van Ham P, Peltier A, Pasteels JL, et al. Classification strategies for the grading of renal cell carcinomas, based on nuclear morphometry and densitometry. J Pathol 1997;183:141-50.
48. Sanjuan X, Fernandez PL, Castells A, Castronovo V, Van Den Brule F, Liu FT, et al. Differential expression of galectin-3 and galectin-1 in colorectal cancer progression. Gastroenterology 1997;113:1906-15.
49. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000;6:138-993.
50. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93:6737-42.
51. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-54.
52. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactosidebinding protein galectin-3. Gastroenterology 1998;115:287-96.
53. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 2001;19:913-9.
54. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276:35917-23.
55. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998;4:707-14.
56. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999;5:181-91.
57. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999;264:751-8.
58. Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T, et al. An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumorassociated angiogenesis. Cytokine 2000;12:309-14.
59. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998;9:757-63.
60. Gabius HJ. Probing, the cons and pros of lectin-induced immunomodulation: case studies for the mistletoe lectin and galectin-1. Biochimie 2001;83:659-66.
61. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12:33-40.
62. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159:2159-65.